Distinguishing the progression of an endometrioma: Benign or malignant?

Ercan Bastu, Ercan Baştu, Onder S, Semen Onder, Semen Önder, Demiral I, İrem Demiral, Mehmet Özsürmeli, Ozsurmeli M, Mehmet Ozsurmeli, Gülşah Keskin, Keskin G, Gulsah Keskin, Ozguc Takmaz, Özgüç Takmaz, Selin Ozaltin, Selin Özaltın, Hüsnü Görgen, Husnu Gorgen, Gorgen H, Mete Gungor, Mete Güngör, Yavuz E, Ekrem Yavuz, Faruk Buyru, Buyru F
European journal of obstetrics, gynecology, and reproductive biology · 2018 · vol. 230 , pp. 79–84 · doi:10.1016/j.ejogrb.2018.09.026 · PMID:30245441 · W2889575303
Observational OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigates the differences between benign endometriomas and malignant endometrioid ovarian cancers to improve diagnostic accuracy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To elucidate the immunohistochemical (IHC) differences of endometrioma tissues that may have the potential to progress to ovarian clear cell carcinoma (OCCC) by using KRAS, HNF1β, PIK3CA, PPP2R1A, and ARID1A as biomarkers. STUDY DESIGN: This is a retrospective clinical study, which was conducted in an university hospital. The groups comprised 14 patients with endometrioma resection who later developed OCCC (non-healthy endometrioma-case group) and 66 patients with endometrioma resection who did not develop ovarian cancer in subsequent follow-ups (healthy endometrium-control group). IHC staining with KRAS, HNF1β, PIK3CA, PPP2R1A, and ARID1A antibodies was performed in paraffin blocks of endometriomas obtained in both groups. For KRAS, PIK3CA, PPP2R1A, and ARID1A, cell staining intensity on a scale from 0 (negative) to 3 (strongly positive), and for HNF1β, the percentage of stained cells (0-5) and the intensity of staining (0-3) were scored. RESULTS: KRAS, HNF1β, PIK3CA, PPP2R1A, and ARID1A were overexpressed in the case group samples compared with the endometrioma samples in the epithelial cells, and ARID1A and KRAS in the stroma were overexpressed in the case group samples compared with the matched control samples. CONCLUSIONS: KRAS, HNF1β, PIK3CA, PPP2R1A, and ARID1A immunostaining scores in endometriomas previous to OCCC were significantly different than in endometriomas with no malignancy occurring in subsequent follow-ups, and were single predictors of OCCC. Hence, immunostaining with these biomarkers may be a method of identifying patients with endometrioma who have the potential to develop OCCC.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Adenocarcinoma, Clear Cell Endometriosis Ovarian Neoplasms Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adult Adult Biomarkers Biomarkers Biomarkers Case-Control Studies Case-Control Studies Class I Phosphatidylinositol 3-Kinases Class I Phosphatidylinositol 3-Kinases Class I Phosphatidylinositol 3-Kinases Disease Progression Disease Progression DNA-Binding Proteins DNA-Binding Proteins

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (72)

Cited by (7)

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:22:59.998548+00:00
unpaywall
last seen: 2026-10-26T06:31:53.434635+00:00
License: CC0 · commercial use OK